Zimmer Biomet (NYSE:ZBH) Downgraded to “Hold” Rating by Wall Street Zen

Zimmer Biomet (NYSE:ZBH) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other analysts have also weighed in on ZBH. Canaccord Genuity Group reduced their price target on shares of Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a research note on Monday, November 10th. Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Wednesday, January 21st. Stifel Nicolaus set a $110.00 price target on Zimmer Biomet in a research note on Wednesday, November 5th. Sanford C. Bernstein lifted their price target on Zimmer Biomet from $97.00 to $99.00 and gave the company a “market perform” rating in a research report on Friday, January 9th. Finally, Robert W. Baird restated a “neutral” rating and issued a $100.00 price objective (down previously from $117.00) on shares of Zimmer Biomet in a report on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and a consensus target price of $106.20.

Zimmer Biomet Trading Up 1.2%

Zimmer Biomet stock opened at $96.32 on Friday. The firm has a 50-day moving average price of $90.10 and a two-hundred day moving average price of $95.64. Zimmer Biomet has a 52-week low of $84.59 and a 52-week high of $114.44. The firm has a market capitalization of $19.09 billion, a price-to-earnings ratio of 27.21, a PEG ratio of 1.95 and a beta of 0.62. The company has a quick ratio of 1.39, a current ratio of 1.98 and a debt-to-equity ratio of 0.55.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The business had revenue of $2.24 billion during the quarter, compared to the consensus estimate of $2.22 billion. During the same period in the previous year, the firm posted $2.31 earnings per share. The business’s revenue was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Sell-side analysts expect that Zimmer Biomet will post 8.22 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Kestra Advisory Services LLC lifted its position in shares of Zimmer Biomet by 15.4% in the fourth quarter. Kestra Advisory Services LLC now owns 7,414 shares of the medical equipment provider’s stock worth $667,000 after purchasing an additional 992 shares in the last quarter. Transamerica Financial Advisors LLC increased its stake in Zimmer Biomet by 45.4% in the 4th quarter. Transamerica Financial Advisors LLC now owns 1,261 shares of the medical equipment provider’s stock valued at $114,000 after buying an additional 394 shares during the period. Ontario Teachers Pension Plan Board purchased a new stake in Zimmer Biomet in the 4th quarter worth approximately $10,394,000. The Manufacturers Life Insurance Company boosted its stake in shares of Zimmer Biomet by 30.5% during the 4th quarter. The Manufacturers Life Insurance Company now owns 1,544,646 shares of the medical equipment provider’s stock valued at $139,054,000 after buying an additional 360,624 shares during the period. Finally, Bridgewater Associates LP boosted its stake in shares of Zimmer Biomet by 148.8% during the 4th quarter. Bridgewater Associates LP now owns 31,228 shares of the medical equipment provider’s stock valued at $2,808,000 after buying an additional 18,679 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.